Participant demographics
| Participant characteristics . | Data . |
|---|---|
| Age, mean ± SD (range), y | 55.05 ± 13.83 (19-76) |
| Sex | |
| Male | 91 (58) |
| Female | 67 (42) |
| Race | |
| White | 137 (87) |
| Asian | 7 (4) |
| Black or African-American | 4 (3) |
| Other | 10 (6) |
| Primary indication for transplant | |
| AML | 53 (34) |
| MDS | 29 (18) |
| ALL | 24 (15) |
| MPD | 12 (8) |
| Anemia, red cell disorder | 9 (6) |
| NHL | 10 (6) |
| Other* | 21 (13) |
| Regimen | |
| Myeloablative | 55 (35) |
| Nonmyeloablative | 103 (65) |
| Donor | |
| Matched related | 24 (15) |
| Mismatched related | 23 (15) |
| Matched unrelated | 87 (55) |
| Mismatched unrelated | 24 (15) |
| Source of stem cells | |
| Peripheral blood | 118 (75) |
| Bone marrow | 37 (23) |
| Cord blood | 3 (2) |
| GVHD prophylaxis medications | |
| Tacrolimus | 155 (98) |
| Sirolimus | 54 (34) |
| Methotrexate | 98 (62) |
| Mycophenolate mofetil | 39 (25) |
| CD34 selection | 1 (1) |
| Other | 38 (24) |
| Acute GVHD | 48 (30) |
| Skin | 41 (85) |
| Gastrointestinal | 13 (27) |
| Liver | 4 (8) |
| Participant characteristics . | Data . |
|---|---|
| Age, mean ± SD (range), y | 55.05 ± 13.83 (19-76) |
| Sex | |
| Male | 91 (58) |
| Female | 67 (42) |
| Race | |
| White | 137 (87) |
| Asian | 7 (4) |
| Black or African-American | 4 (3) |
| Other | 10 (6) |
| Primary indication for transplant | |
| AML | 53 (34) |
| MDS | 29 (18) |
| ALL | 24 (15) |
| MPD | 12 (8) |
| Anemia, red cell disorder | 9 (6) |
| NHL | 10 (6) |
| Other* | 21 (13) |
| Regimen | |
| Myeloablative | 55 (35) |
| Nonmyeloablative | 103 (65) |
| Donor | |
| Matched related | 24 (15) |
| Mismatched related | 23 (15) |
| Matched unrelated | 87 (55) |
| Mismatched unrelated | 24 (15) |
| Source of stem cells | |
| Peripheral blood | 118 (75) |
| Bone marrow | 37 (23) |
| Cord blood | 3 (2) |
| GVHD prophylaxis medications | |
| Tacrolimus | 155 (98) |
| Sirolimus | 54 (34) |
| Methotrexate | 98 (62) |
| Mycophenolate mofetil | 39 (25) |
| CD34 selection | 1 (1) |
| Other | 38 (24) |
| Acute GVHD | 48 (30) |
| Skin | 41 (85) |
| Gastrointestinal | 13 (27) |
| Liver | 4 (8) |
Unless otherwise indicated, data are n (%).
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; NHL, non-Hodgkin lymphoma; SD, standard deviation.
CLL, chronic lymphocytic leukemia; CML, chronic myelogenous; HL, Hodgkin lymphoma; other indication.